DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Sunday. The firm issued a hold rating on the stock.

A number of other research firms also recently commented on DBVT. JMP Securities reaffirmed a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a report on Friday, January 10th. HC Wainwright raised their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Trading Up 11.6 %

NASDAQ:DBVT opened at $4.53 on Friday. The company has a market capitalization of $93.18 million, a P/E ratio of -1.01 and a beta of 0.67. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $9.40. The firm has a fifty day simple moving average of $3.79 and a 200-day simple moving average of $3.87.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($1.90) by $1.10. The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.17 million. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. Equities analysts forecast that DBV Technologies will post -7.05 EPS for the current year.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.